Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Atara Biotherapeutics Inc ATRA

Healthcare Biotechnology
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ATRA)

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

Business Wire 20 hours ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 6 days ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 5, 2024

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Business Wire March 28, 2024

Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy

Business Wire February 29, 2024

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference

Business Wire February 28, 2024

Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Business Wire February 14, 2024

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

Business Wire January 31, 2024

Atara Biotherapeutics Announces $15 Million Registered Direct Offering

Business Wire January 8, 2024
View More News ››

Opinion & Analysis (NDAQ:ATRA)

Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'

Streetwise Reports May 28, 2020
View More Opinion ››

Bullboard Posts (NDAQ:ATRA)

$iMIN making moves in Ethereum Crypto !! 🚀🚀🚀🚀🚀

iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining Vancouver...
Saaaa1 - May 6, 2021

Excitement Builds in the High-Growth High-Momentum Biotech S

Excitement Builds in the High-Growth High-Momentum Biotech Space $CRSP,$NTRB,$ATRA https://www.wallstreetpr.com/excitement-builds-in...
wallstreetfun - June 13, 2018

Sell

Just opened up at $200k - wow, I'm taking my profits
leblereau - November 10, 2014
View more Bullboard ››

Masivo Silver Corp.

Masivo Silver Corp.

Masivo Silver Corp. is a Canada-based junior silver and gold mining exploration company. The Company is in the business of ...
View More »